Reuters logo
BRIEF-AC Immune to get milestone payment for Alzheimer drug
November 2, 2017 / 10:40 AM / 20 days ago

BRIEF-AC Immune to get milestone payment for Alzheimer drug

Nov 2 (Reuters) - AC Immune Ltd

* Says to receive milestone payment for anti-tau antibody moving into phase 2 trial for Alzheimer’s disease ‍​

* Says upon the dosing of the first patient in the phase 2 clinical trial, AC Immune becomes eligible to receive a milestone payment of CHF 14 million, which is expected to be paid in the fourth quarter of 2017‍​

* Says this will be the third milestone payment under the 2012 strategic collaboration and licensing agreement with Genentech Source text for Eikon: Further company coverage: (Reporting By Michael Shields)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below